Marlo Blazer

823 total citations
30 papers, 567 citations indexed

About

Marlo Blazer is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Marlo Blazer has authored 30 papers receiving a total of 567 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 16 papers in Hematology and 9 papers in Molecular Biology. Recurrent topics in Marlo Blazer's work include Multiple Myeloma Research and Treatments (10 papers), Protein Degradation and Inhibitors (8 papers) and Colorectal Cancer Treatments and Studies (6 papers). Marlo Blazer is often cited by papers focused on Multiple Myeloma Research and Treatments (10 papers), Protein Degradation and Inhibitors (8 papers) and Colorectal Cancer Treatments and Studies (6 papers). Marlo Blazer collaborates with scholars based in United States, United Kingdom and Greece. Marlo Blazer's co-authors include Tanios Bekaii‐Saab, Eileen Farrelly, Joshua Reardon, Aditya Raju, Dorothy Romanus, Carl Schmidt, Christina Wu, Richard M. Goldberg, Gary Phillips and Peter Muscarella and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Cancer.

In The Last Decade

Marlo Blazer

29 papers receiving 557 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marlo Blazer United States 13 386 211 143 131 118 30 567
Anna Potamianou Greece 13 481 1.2× 196 0.9× 118 0.8× 142 1.1× 198 1.7× 37 716
A. McDonald United Kingdom 14 409 1.1× 118 0.6× 210 1.5× 203 1.5× 127 1.1× 19 721
Rebecca S. Tidwell United States 11 351 0.9× 111 0.5× 127 0.9× 199 1.5× 64 0.5× 40 617
Stefanie Hieke Germany 9 250 0.6× 290 1.4× 195 1.4× 81 0.6× 33 0.3× 18 572
Rashmi Tondon United States 14 296 0.8× 53 0.3× 132 0.9× 63 0.5× 143 1.2× 33 630
Lothar Müller Germany 13 424 1.1× 64 0.3× 163 1.1× 269 2.1× 131 1.1× 71 850
M Hunt United States 13 590 1.5× 408 1.9× 106 0.7× 267 2.0× 157 1.3× 21 1000
Jonathan C. Yau United States 17 454 1.2× 190 0.9× 128 0.9× 197 1.5× 144 1.2× 33 768
Tadahiko Igarashi Japan 14 296 0.8× 143 0.7× 131 0.9× 55 0.4× 45 0.4× 45 577
Cheryl Sickles United States 6 266 0.7× 102 0.5× 58 0.4× 132 1.0× 141 1.2× 7 637

Countries citing papers authored by Marlo Blazer

Since Specialization
Citations

This map shows the geographic impact of Marlo Blazer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marlo Blazer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marlo Blazer more than expected).

Fields of papers citing papers by Marlo Blazer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marlo Blazer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marlo Blazer. The network helps show where Marlo Blazer may publish in the future.

Co-authorship network of co-authors of Marlo Blazer

This figure shows the co-authorship network connecting the top 25 collaborators of Marlo Blazer. A scholar is included among the top collaborators of Marlo Blazer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marlo Blazer. Marlo Blazer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chari, Ajai, Dorothy Romanus, Antonio Palumbo, et al.. (2019). Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 20(1). 8–17.e16. 69 indexed citations
2.
3.
Bell, Jill A., Aaron Galaznik, Marlo Blazer, et al.. (2018). Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States. PharmacoEconomics - Open. 3(2). 237–245. 14 indexed citations
4.
Hari, Parameswaran, Marlo Blazer, Aditya Raju, et al.. (2018). Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA. Expert Review of Hematology. 12(1). 71–79. 3 indexed citations
5.
Bell, Jill A., Aaron Galaznik, Eileen Farrelly, et al.. (2018). Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States. Leukemia Research. 71. 27–33. 25 indexed citations
6.
Hari, Parameswaran, Dorothy Romanus, Antonio Palumbo, et al.. (2018). Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States. Clinical Lymphoma Myeloma & Leukemia. 18(2). 152–160. 30 indexed citations
7.
8.
Hari, Parameswaran, Dorothy Romanus, Katarina Luptakova, et al.. (2017). The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies. Journal of Geriatric Oncology. 9(2). 138–144. 28 indexed citations
9.
Romanus, Dorothy, Aditya Raju, Candice Yong, et al.. (2017). Association Between Treatment Regimen Type in Second-Line Therapy (2LT) and Duration of Therapy (DOT) & Time To Next Treatment (TTNT) in a United States (US) Relapsed/Refractory Multiple Myeloma (RRMM) Cohort. Clinical Lymphoma Myeloma & Leukemia. 17(1). e81–e82. 2 indexed citations
10.
Gordan, Lucio, Amy Grogg, Marlo Blazer, & Barry Fortner. (2017). Unintended Consequences in Cancer Care Delivery Created by the Medicare Part B Proposal: Is the Clinical Rationale for the Experiment Flawed?. Journal of Oncology Practice. 13(2). e139–e151. 1 indexed citations
11.
Romanus, Dorothy, Aditya Raju, Brian Seal, et al.. (2017). Treatment (tx) Patterns & Outcomes by Line of Therapy (LOT) in a Large United States (US) Cohort of Transplant-Ineligible Patients (pts) with Multiple Myeloma in the Era of Novel Agents. Clinical Lymphoma Myeloma & Leukemia. 17(1). e80–e81. 1 indexed citations
12.
13.
Vargo, Craig, Marlo Blazer, Joshua Reardon, Martha Gulati, & Tanios Bekaii‐Saab. (2015). Successful Completion of Adjuvant Chemotherapy in a Patient With Colon Cancer Experiencing 5-Fluorouracil–Induced Cardiac Vasospasm. Clinical Colorectal Cancer. 15(2). e61–e63. 6 indexed citations
14.
Wu, Christina, Sameh Mikhail, Lai Wei, et al.. (2015). A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers. British Journal of Cancer. 113(2). 220–225. 9 indexed citations
15.
Blazer, Marlo, Christina Wu, Richard M. Goldberg, et al.. (2014). Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas. Annals of Surgical Oncology. 22(4). 1153–1159. 180 indexed citations
16.
Blazer, Marlo, Christina Wu, Richard M. Goldberg, et al.. (2014). Tolerability and efficacy of modified FOLFIRINOX (mFOLFIRINOX) in patients with borderline-resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAURPC).. Journal of Clinical Oncology. 32(3_suppl). 275–275. 12 indexed citations
17.
Berger, Michael, Marlo Blazer, Brooke Crawford, et al.. (2013). Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy. Supportive Care in Cancer. 21(10). 2845–2851. 19 indexed citations
18.
Blazer, Marlo, et al.. (2013). Palonosetron for the prevention of chemotherapy-induced nausea and vomiting. Expert Review of Anticancer Therapy. 13(8). 919–936. 5 indexed citations
19.
20.
Martin, Ludmila Katherine, Lai Wei, Jeffrey S. Rose, et al.. (2012). Yttrium-90 Radioembolization as Salvage Therapy for Colorectal Cancer With Liver Metastases. Clinical Colorectal Cancer. 11(3). 195–199. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anna Potamianou Breakdown of academic impact, for papers by A. McDonald Breakdown of academic impact, for papers by Rebecca S. Tidwell Breakdown of academic impact, for papers by Stefanie Hieke Breakdown of academic impact, for papers by Rashmi Tondon Breakdown of academic impact, for papers by Lothar Müller Breakdown of academic impact, for papers by M Hunt Breakdown of academic impact, for papers by Jonathan C. Yau Breakdown of academic impact, for papers by Tadahiko Igarashi Breakdown of academic impact, for papers by Cheryl Sickles
Rankless by CCL
2026